ReviewVox sanguinis2021
Severe acute respiratory syndrome coronavirus-2: implications for blood safety and sufficiency.
Review in Vox sanguinis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Impact of the COVID-19 Pandemic on the Usage of Blood for Transfusions: A 2-Year Experience from a Tertiary Center in Korea.Vaccines · 2023Article
- Use of blood products during the first months of COVID-19 pandemic period: A single center report.Heliyon · 2023Article
- Monitoring Prevalence and Persistence of Environmental Contamination by SARS-CoV-2 RNA in a Makeshift Hospital for Asymptomatic and Very Mild COVID-19 Patients.International journal of public health · 2023Article
- SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network.Blood transfusion = Trasfusione del sangue · 2022Article
- Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Review
- SARS-CoV-2 and blood donations in Portugal, June-July 2020.Journal of medical virology · 2022Article
- Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Article
- Detection rate of SARS-CoV-2 RNA in relation to isolation time and environmental surface type.Frontiers in public health · 2022Article
- A survey of laboratory biosafety and protective measures in blood transfusion departments during the COVID-19 pandemic.Vox sanguinis · 2021Observational
- Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation.Transplantation and cellular therapy · 2021Article
- Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 Disease.medRxiv : the preprint server for health sciences · 2021Article
- A study to identify severe acute respiratory syndrome coronavirus 2 in erythrocytes of patients suffering from coronavirus disease-19 at an Apex tertiary care institute in Andhra Pradesh, South India.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus, first identified in China at the end of 2019 and has now caused a worldwide pandemic. In this review, we provide an overview of the implications of SARS-CoV-2 for blood safety and sufficiency. MATERIAL AND
methodWe searched the PubMed database, the preprint sites bioRxiv and medRxiv, the websites of the World Health Organization, European Centre for Disease Prevention and Control, the US Communicable Diseases Center and monitored ProMed updates.
resultsAn estimated 15%-46% of SARS-CoV-2 infections are asymptomatic. The reported mean incubation period is 3 to 7 days with a range of 1-14 days. The blood phase of SARS-CoV-2 appears to be brief and low level, with RNAaemia detectable in only a small proportion of patients, typically associated with more severe disease and not demonstrated to be infectious virus. An asymptomatic blood phase has not been demonstrated. Given these characteristics of SARS-CoV-2 infection and the absence of reported transfusion transmission (TT), the TT risk is currently theoretical. To mitigate any potential TT risk, but more importantly to prevent respiratory transmission in donor centres, blood centres can implement donor deferral policies based on travel, disease status or potential risk of exposure.
conclusionThe TT risk of SARS-CoV-2 appears to be low. The biggest risk to blood services in the current COVID-19 pandemic is to maintain the sufficiency of the blood supply while minimizing respiratory transmission of SARS-CoV-19 to donors and staff while donating blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.